Prognostic significance of cyclin D1 gene (CCND1) polymorphism in epithelial ovarian cancer

International Journal of Gynecological Cancer

Volumn 9, Issue 4, 1999, Pages 342-347

  Dhar, K K ^a,b   Branigan, K ^a   Howells, R E J ^b   Musgrove, C ^c   Jones, P W ^d   Strange, R C ^a   Fryer, A A ^a   Redman, C W E ^b   Hoban, P R ^a  

^a KEELE UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b DEPARTMENT OF OBSTETRICS AND GYNAECOLOGY   (United Kingdom)

^c UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^d KEELE UNIVERSITY   (United Kingdom)

Author keywords

Cell cycle; Cyclin D1; Ovarian cancer; Polymorphism; Progression free interval; Survival

Indexed keywords

CYCLIN D1; DNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TUMOR DIFFERENTIATION; TUMOR VOLUME;

EID: 0032812688     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.1999.99048.x     Document Type: Article

References (27)

1. Office of Population Census and Surveys. Cancer Statistics MBI Publishers no. 22, HMSO, Books 1994.
2. Chang J, Bridgewater J, Gore M et al. Non-surgical aspects of ovarian cancer. Lancet 1994;343:335-41.
3. Rubin SC, Hoskins WJ, Saigo PE. Prognostic factors for recurrence following negative second look laparotomy in ovarian cancer patients treated with platinum based chemotherapy. Gynecol Oncol 1991;42:137-41.
4. Pines J. Cyclins, CDKs and cancer. Semin Cancer Biol 1995;6:63-72.
5. Sherr CJ. Cancer Cell Cycles. Science 1996;274:1672-7.
6. Callender T, El-Naggar AK, Lee MS, Frankenthaler R, Luna MA, Batsakis JG. PRAD-1 (CCND1) /Cyclin D1 oncogene amplification in head and neck squamous cell carcinoma. Cancer 1994;74:152-8.
7. Gillet C, Fantl V, Smith R et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994;54:1812-7.
8. Betticher D, Heighway J, Haselton PS et al. Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Brit J Cancer 1996;73:294-300.
9. Dhar KK, Branigan K, Hand P et al. Analysis of Cyclin D1 amplification and overexpression in ovarian cancer. Acta Obstetricia Gynaecologica Scand 1997;76 (Suppl.167:5): 19 (Abstract).
10. Michalides R, van Veelen N, Hart A, Loftus B, Wientjens E, Balm A. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res 1995; 55:975-8.
11. Jares P, Fernandez PL, Campo E et al. PRAD-1/Cyclin D1 gene amplification correlates with messenger mRNA overexpression and tumour progression in human laryngeal carcinomas. Cancer Res 1994;54:4813-7.
12. Maeda K, Chung Y, Kang S et al. Cyclin D1 overexpression and prognosis in colorectal adenocarcinoma. Oncology 1998;55:145-51.
13. Shin KY, Kong G, Kim WS, Lee TY, Woo YN, Lee JD. Overexpression of cyclin D1 correlates with early recurrence in superficial bladder cancers. Brit J Cancer 1997; 75:1788-92.
14. Ishikawa T, Furihata M, Ohtsuki Y, Murakami H, Inoue A, Ogoshi S. Cyclin D1 overexpression related to retinoblastoma protein expression as a prognostic marker in human oesophageal squamous cell carcinoma. Brit J Cancer 1998;77:92-7.
15. Gillett C, Smith P, Gregory W et al. Cyclin Dl and prognosis in human breast cancer, Int J Cancer 1996;69:92-9.
16. Betticher D, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J. Alternate splicing produces a novel cyclin D1 transcript. Oncogene 1995;11:1005-11.
17. Matthias C, Branigan K, Jahnke V et al. Polymorphism within the Cyclin D1 gene is associated with prognosis in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 1998;4:2411-8.
18. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: A Laboratory Manual, 2nd edn. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.
19. Hung W, Chai C, Huang J, Chuang L. Expression of cyclin D1 and c-Ki-ras gene product in human epithelial ovarian tumors. Hum Pathol 1996;27:1324-8.
20. Worsley SD, Ponder BAJ, Daves BR. Overexpression of cyclin D1 in epithelial ovarian cancers. Gynecol Oncol 1997;64:189-95.
21. Sykes PH, Quinn MA, Rome RM. Ovarian tumours of low malignant potential: a retrospective study of 234 patients, Int J Gynecol Cancer 1997;7:218-26.
22. Bjrge T, Engeland A, Hansen S, Trope CG. Trends in the incidence of ovarian cancer and borderline tumours in Norway. 1954-93. Int J Cancer 1997;71:780-6.
23. Warwick J, Kehoe S, Earl H, Luesley D, Redman C, Chan KK. Long term follow up of patients with advanced ovarian cancer treated in randomised clinical trials. Br J Cancer 1995;72:1513-7.
24. Cervantes A. Prognostic factors in advanced ovarian cancer, Int J Gynecol Cancer 1997;7:4-8.
25. Motokura T, Bloom T, Kim HG et al. A novel cyclin encoded by a bcl-1 linked candidate oncogene. Nature 1991;350:512-5.
26. Pines J. Cyclins and their associated cyclin-dependent kinases in the human cell cycle. Biochem Soc Trans 1993;21:921-5.
27. Sawa H, Ohshima A, Ukita H et al. Alternatively spliced forms of cyclin D1 modulate entry into the cell cycle in an inverse manner. Oncogene 1998;16:1701-12.